Can-Fite Biopharma Ltd ADR (CANF)

$3.91 -0.72 (-15.55%)
Market Cap 2.56M
Revenue (ttm) 410,000.00
Net Income (ttm) -9.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,397.56%
Debt to Equity Ratio 0.00
Volume 932,500
Avg Vol 2,290,342
Day's Range N/A - N/A
Shares Out 655,000.00
Stochastic %K 39%
Beta 1.11
Analysts Strong Sell
Price Target $5.50

Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic c...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 3 924 1114
Fax: 972 3 924 9378
Address:
26 Ben Gurion Street, Ramat Gan, Israel
Breton2018
Breton2018 Jul. 3 at 2:57 PM
$CANF 5$ next week ?
0 · Reply
gsd1
gsd1 Jul. 2 at 8:04 PM
$CANF Great day. started loading a bit early at 4.16. I kept loading in 3.60's and 3:70's. the future is bright. 2 phase III in progress. lots more in the pipeline and partnerships.
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:34 PM
$CANF 80k shares dumped on that long red candle down … it wont recover above $3.9 , it will dloely trash below $3 unless it can recover that 80k shares dumped
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:15 PM
$CANF more idiots buying on green candles lmao so dumb :(
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:12 PM
$CANF told ya fools gold!!!!! only idiots will fall for these scam upgrade … these anaysts pair up with these company tondo scam offering $$$$$$$$
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:08 PM
$CANF 3.25 only idiots will hold above $3 …..
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 4:03 PM
$CANF only idiots and rookies will hold above $3
0 · Reply
RobertKalermen
RobertKalermen Jul. 2 at 3:59 PM
$CANF My post from before Tuesday news: I pioneered this research in 1978 at the Univ of Michigan. This dump, I believe was due to the $13 billion of Spy puts that came in minutes before mkt close Friday, driving down stocks.It got picked up within minutes. And Having Japan recognize CANF patent is very supportive of legitamacy. IMO..this is a buying opportunity. I can't speak to the stock moves (on many, many stocks these days)..but knowing the science I feel secure here. I will trade it to $5..
0 · Reply
RobertKalermen
RobertKalermen Jul. 2 at 3:57 PM
$CANF Bullish in the long term..but taken in the reality of the players here, AND THE FACT that last Friday it hit $2.36 after similar move up on supportive Japan news. I dont think its safe to buy again until below $2.60. IMO, both news stories were supportive, but not generating the "real sales" for stockholders to get this excited..this early. I'll repost that post from the day before the cancer news
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:53 PM
$CANF red candle soon
0 · Reply
Latest News on CANF
CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8

2026-07-02T13:07:25.000Z - 2 days ago

CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

2026-07-02T10:00:15.000Z - 2 days ago

Can-Fite BioPharma price target raised to $8 from $5 at H.C. Wainwright

Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study

2026-07-01T12:40:34.000Z - 3 days ago

Can-Fite BioPharma (CANF) Reports Positive Results in Namodenoson Study

Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market

2026-07-01T11:57:57.000Z - 3 days ago

Can-Fite's Namodenoson Shows Survival Benefits In Pancreatic Cancer; Stock Jumps Pre-Market

Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint

2026-07-01T11:05:11.000Z - 3 days ago

Can-Fite BioPharma announces Namodenoson study meets primary safety endpoint

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Wed, 01 Jul 2026 07:00:00 -0400 - 3 days ago

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment

2026-06-26T12:31:28.000Z - 8 days ago

Can-Fite BioPharma (CANF) Secures Key Patent for Fat Loss Treatment

Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists

2026-06-26T11:05:19.000Z - 8 days ago

Can-Fite BioPharma secures Japanese patent for A3 adenosine receptor agonists

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Fri, 26 Jun 2026 07:00:00 -0400 - 8 days ago

Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Mon, 22 Jun 2026 07:00:00 -0400 - 12 days ago

Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

Wed, 17 Jun 2026 07:00:00 -0400 - 17 days ago

Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism

Tue, 02 Jun 2026 07:00:00 -0400 - 4 weeks ago

Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Mon, 18 May 2026 07:00:00 -0400 - 6 weeks ago

Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

2026-05-13T13:49:05.000Z - 7 weeks ago

Can-Fite BioPharma upgraded to Buy from Hold at D. Boral Capital

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Wed, 13 May 2026 07:00:00 -0400 - 7 weeks ago

Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

2026-05-12T10:49:37.000Z - 7 weeks ago

Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Thu, 30 Apr 2026 08:31:00 -0400 - 2 months ago

Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months

Can-Fite BioPharma Registration statement: Registration filing

Mar 31, 2026, 8:00 AM EDT - 3 months ago

Can-Fite BioPharma Registration statement: Registration filing

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

2026-03-31T10:16:55.000Z - 3 months ago

Can-Fite BioPharma files to sell 3.29M ordinary shares for holders

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

2026-03-30T22:03:00.000Z - 3 months ago

Can-Fite BioPharma (CANF) Advances Osteoarthritis Treatment for Dogs

Can-Fite BioPharma completes enrollment in Piclidenoson study

2026-03-30T11:37:18.000Z - 3 months ago

Can-Fite BioPharma completes enrollment in Piclidenoson study

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Mon, 30 Mar 2026 07:20:00 -0400 - 3 months ago

Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026

Can-Fite BioPharma Annual report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 3 months ago

Can-Fite BioPharma Annual report: Q4 2025

Can-Fite BioPharma Quarterly report: Q4 2025

Mar 26, 2026, 9:30 AM EDT - 3 months ago

Can-Fite BioPharma Quarterly report: Q4 2025

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Thu, 26 Mar 2026 09:27:00 -0400 - 3 months ago

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

2026-03-17T13:28:03.000Z - 3 months ago

Can-Fite BioPharma (CANF) Secures Key Patent for Obesity Treatment

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

2026-03-17T11:50:14.000Z - 3 months ago

Can-Fite BioPharma announces Israeli patent allowance for namodenoson

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Tue, 17 Mar 2026 07:47:00 -0400 - 3 months ago

Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

2026-03-04T16:50:16.000Z - 4 months ago

Can-Fite's Namodenoson Hits Phase 2a Goal; Raises $4M Via Warrants

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Wed, 04 Mar 2026 10:07:28 -0500 - 4 months ago

Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

2026-03-04T12:34:33.000Z - 4 months ago

Can-Fite BioPharma (CANF) Achieves Positive Results in Pancreatic Cancer Study

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

2026-03-04T12:09:03.000Z - 4 months ago

Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Wed, 04 Mar 2026 07:00:00 -0500 - 4 months ago

Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

2026-02-17T12:36:34.000Z - 4 months ago

Can-Fite BioPharma (CANF) Unveils Promising Obesity Study Results

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

2026-02-17T12:15:35.000Z - 4 months ago

Can-Fite BioPharma announces publication of anti-obesity effect of namodenoson

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

2026-02-09T12:30:05.000Z - 5 months ago

Can-Fite (CANF) Gains Canadian Patent for Anti-Obesity Drug Namodenoson

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

2026-02-09T12:15:27.000Z - 5 months ago

Can-Fite BioPharma receives Canadian patent allowance for namodenoson

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

2026-02-05T12:33:49.000Z - 5 months ago

Can-Fite BioPharma (CANF) Treatment Aids Successful Liver Transplant

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

2026-02-05T12:17:59.000Z - 5 months ago

Can-Fite announces patient with liver cirrhosis treated with Namodenoson

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

2026-01-20T12:37:35.000Z - 5 months ago

Can-Fite BioPharma (CANF) Completes Patient Enrollment in Pancreatic Cancer Trial

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

2026-01-20T12:10:21.000Z - 5 months ago

Can-Fite completes patient enrollment in Phase 2a study of Namodenoson

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

2025-12-24T15:50:08.000Z - 6 months ago

Can-Fite BioPharma downgraded to Hold from Buy at D. Boral Capital

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

2025-12-23T22:55:20.000Z - 6 months ago

Can-Fite BioPharma (CANF) Announces 1-for-3,000 Reverse Stock Split

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

2025-12-23T22:25:23.000Z - 6 months ago

Can-Fite BioPharma (CANF) Announces Significant Reverse Split

Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

2025-12-23T21:50:11.000Z - 6 months ago

Can-Fite BioPharma announces 1-for-3,000 reverse split, ratio change

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

Tue, 23 Dec 2025 16:46:00 -0500 - 6 months ago

Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

2025-12-17T13:30:15.000Z - 7 months ago

CANF: D. Boral Capital Lowers Price Target But Maintains Buy Rating | CANF Stock News

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

2025-12-16T15:29:50.000Z - 7 months ago

CANF: Can-Fite BioPharma Advances Clinical Trials and Strengthens Financial Position

Can-Fite BioPharma provides clinical, financial update

2025-12-16T14:25:37.000Z - 7 months ago

Can-Fite BioPharma provides clinical, financial update

Can-Fite Provides Update on Clinical and Financial Status

Tue, 16 Dec 2025 09:19:00 -0500 - 7 months ago

Can-Fite Provides Update on Clinical and Financial Status

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

2025-11-24T12:30:24.000Z - 7 months ago

Can-Fite BioPharma (CANF) to Engage in Strategic Collaborations at BioFIT 2025

Can-Fite BioPharma to participate in BioFIT 2025

2025-11-24T12:15:09.000Z - 7 months ago

Can-Fite BioPharma to participate in BioFIT 2025

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

2025-11-20T12:42:31.000Z - 8 months ago

Can-Fite BioPharma (CANF) Secures Patent Approval in Brazil for Erectile Dysfunction Treatment

Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602

2025-11-20T12:05:46.000Z - 8 months ago

Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Nov 20, 2025, 7:00 AM EST - 8 months ago

Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Aug 28, 2025, 8:47 AM EDT - 11 months ago

Can-Fite Reports H1 2025 Financial Results and Clinical Update

Can-Fite BioPharma Quarterly report: Q2 2025

Aug 27, 2025, 6:00 PM EDT - 11 months ago

Can-Fite BioPharma Quarterly report: Q2 2025

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Jul 30, 2025, 7:04 AM EDT - 1 year ago

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Can-Fite Announces Up To $15.0 Million Public Offering

Jul 28, 2025, 12:24 PM EDT - 1 year ago

Can-Fite Announces Up To $15.0 Million Public Offering

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Jul 28, 2025, 7:00 AM EDT - 1 year ago

Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia

Can-Fite BioPharma Registration statement: Registration Filing

Jul 25, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Registration statement: Registration Filing

Can-Fite BioPharma Registration statement: Registration Filing

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Registration statement: Registration Filing

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Apr 17, 2025, 8:55 AM EDT - 1 year ago

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Apr 14, 2025, 2:28 PM EDT - 1 year ago

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

Can-Fite BioPharma Annual report: Q4 2024

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Annual report: Q4 2024

Can-Fite BioPharma Quarterly report: Q4 2024

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Can-Fite BioPharma Quarterly report: Q4 2024

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Mar 20, 2025, 9:45 AM EDT - 1 year ago

Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Mar 19, 2025, 9:00 AM EDT - 1 year ago

Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Mar 3, 2025, 6:00 AM EST - 1 year ago

Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Feb 10, 2025, 7:10 AM EST - 1 year ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Feb 5, 2025, 7:00 AM EST - 1 year ago

Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Dec 30, 2024, 7:00 AM EST - 1 year ago

Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson

Can-Fite BioPharma Transcript: C-level Sitdown

Nov 23, 2024, 7:01 PM EST - 1 year ago

Can-Fite BioPharma Transcript: C-level Sitdown

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Nov 22, 2024, 9:00 AM EST - 1 year ago

60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SXTP

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Nov 11, 2024, 7:00 AM EST - 1 year ago

Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Nov 4, 2024, 7:08 AM EST - 1 year ago

Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia

Can-Fite BioPharma Transcript: Investor Update

Oct 29, 2024, 4:15 PM EDT - 1 year ago

Can-Fite BioPharma Transcript: Investor Update

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

Oct 18, 2024, 9:06 AM EDT - 1 year ago

Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Oct 9, 2024, 7:00 AM EDT - 1 year ago

FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Sep 16, 2024, 7:00 AM EDT - 1 year ago

Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health

Can-Fite BioPharma Registration statement: Registration Filing

Aug 30, 2024, 8:00 AM EDT - 2 years ago

Can-Fite BioPharma Registration statement: Registration Filing

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Aug 29, 2024, 8:15 AM EDT - 2 years ago

Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

Can-Fite BioPharma Earnings release: Q2 2024

Aug 29, 2024, 7:00 AM EDT - 2 years ago

Can-Fite BioPharma Earnings release: Q2 2024

Can-Fite BioPharma Transcript: C-level Sitdown

Aug 10, 2024, 7:00 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: C-level Sitdown

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Aug 9, 2024, 9:00 AM EDT - 2 years ago

OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

OSTX

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Aug 8, 2024, 7:01 PM EDT - 2 years ago

Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds

Can-Fite BioPharma Transcript: Investor Update

Aug 8, 2024, 4:15 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: Investor Update

Can-Fite Provides Namodenoson Patent Update

Jul 29, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Provides Namodenoson Patent Update

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Jul 17, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Jul 11, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Jun 28, 2024, 7:00 AM EDT - 2 years ago

Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Can-Fite's Partner Vetbiolix

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Jun 24, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: Breakthrough Findings Demonstrate Namodenoson Anti-cancer and Protective Effect Mechanism in the Liver

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Jun 10, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite BioPharma Transcript: Investor Update

Jun 6, 2024, 4:15 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: Investor Update

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Jun 5, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Updates on its Advanced Liver Cancer Pivotal Phase 3 Study

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

May 29, 2024, 7:00 AM EDT - 2 years ago

Independent Scientists Published a Review Article Demonstrating That Can-Fite Drugs Have Therapeutic Effects on Heart Diseases

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

May 27, 2024, 7:00 AM EDT - 2 years ago

Can-Fite to Participate in Partnering Meetings at Bio International Convention 2024

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

May 23, 2024, 7:00 AM EDT - 2 years ago

Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on June 6

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

May 13, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: 75 Oncologists and Coordinators from Europe US and Israel Participated in a Conference Aimed at Accelerating Patient Enrolment for the Pivotal Phase 3 Advanced Liver Cancer Study

Can-Fite BioPharma Transcript: C-level Sitdown

May 11, 2024, 7:00 PM EDT - 2 years ago

Can-Fite BioPharma Transcript: C-level Sitdown

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

May 10, 2024, 9:00 AM EDT - 2 years ago

Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

NTRB

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

May 9, 2024, 7:00 AM EDT - 2 years ago

Can-Fite: FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

May 6, 2024, 7:00 AM EDT - 2 years ago

Can-Fite Received Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

Breton2018
Breton2018 Jul. 3 at 2:57 PM
$CANF 5$ next week ?
0 · Reply
gsd1
gsd1 Jul. 2 at 8:04 PM
$CANF Great day. started loading a bit early at 4.16. I kept loading in 3.60's and 3:70's. the future is bright. 2 phase III in progress. lots more in the pipeline and partnerships.
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:34 PM
$CANF 80k shares dumped on that long red candle down … it wont recover above $3.9 , it will dloely trash below $3 unless it can recover that 80k shares dumped
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:15 PM
$CANF more idiots buying on green candles lmao so dumb :(
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:12 PM
$CANF told ya fools gold!!!!! only idiots will fall for these scam upgrade … these anaysts pair up with these company tondo scam offering $$$$$$$$
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 5:08 PM
$CANF 3.25 only idiots will hold above $3 …..
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 4:03 PM
$CANF only idiots and rookies will hold above $3
0 · Reply
RobertKalermen
RobertKalermen Jul. 2 at 3:59 PM
$CANF My post from before Tuesday news: I pioneered this research in 1978 at the Univ of Michigan. This dump, I believe was due to the $13 billion of Spy puts that came in minutes before mkt close Friday, driving down stocks.It got picked up within minutes. And Having Japan recognize CANF patent is very supportive of legitamacy. IMO..this is a buying opportunity. I can't speak to the stock moves (on many, many stocks these days)..but knowing the science I feel secure here. I will trade it to $5..
0 · Reply
RobertKalermen
RobertKalermen Jul. 2 at 3:57 PM
$CANF Bullish in the long term..but taken in the reality of the players here, AND THE FACT that last Friday it hit $2.36 after similar move up on supportive Japan news. I dont think its safe to buy again until below $2.60. IMO, both news stories were supportive, but not generating the "real sales" for stockholders to get this excited..this early. I'll repost that post from the day before the cancer news
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:53 PM
$CANF red candle soon
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:39 PM
$CANF
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:39 PM
$CANF gasd1 is a paid bullish spammers with canf organization lmao working with then ona ponzi scheme . bullish my ass lmao
0 · Reply
gsd1
gsd1 Jul. 2 at 3:36 PM
$CANF This thing is a bargain. I am still buying , long term hold. No worries. 2 phase III trials in progress, numerous partnerships !
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:32 PM
$CANF no one dares to replay to donnie because they know donnie is 100% correct , stay away from this trash scam stock lmao … dilution offering machine haha
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:22 PM
$CANF look at all the idiots that got excited and bought above $4.20 seeing that scam upgrade for $8 and bought smh …….🤦‍♀️….. it never gets old . they are great at what they do haha …… $3.50….$2. soon , and yes i dear them to dliute right now for another time $10 mil free money for them and tank the stock to $.75 cents do then yet another reverse spplitnof 1-50 lmao , yoi know it will come again at idiot investors cost lmao
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 3:07 PM
$CANF ONLY idiots and dumb dumb will still trust this scam EPIC dilution offering machine trash stock lmao
0 · Reply
gsd1
gsd1 Jul. 2 at 2:58 PM
$CANF just bought more @ 4.16 batgain !
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 2:56 PM
$CANF when the bid and the ask is so far apart , you already know this will slowly trash to under $4 … and then 3.50…..$2 soon :( im sorry
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 2:54 PM
$CANF the investors aint falling for this pump for yet another offering soon lol
0 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 2:13 PM
$CANF they desperate to pump the shares with a stupid upgrade lmao . FOOLS gold ……the low volume says it all lol …$3 soon and they hope it will run higher faster so another round of scam offering lol … wont work this time …. this scam atock needs to be delisted !!!!
0 · Reply
rangervs
rangervs Jul. 2 at 2:10 PM
$SDOT reminds me of $HKD run Has the juice! $CANF $SURG
1 · Reply
Donniechen12345
Donniechen12345 Jul. 2 at 1:59 PM
$CANF volume too low , this fake pop wontnhold and will drop 100%
0 · Reply